Meyahealth
Home
ENES
HomeGeneticsGeneMIR146A gene
Back to Gene

MIR146A gene

Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

MIR146A gene

The MIR146A gene provides instructions for microRNA-146a, a molecule that plays a key role in blood cell development and the regulation of platelet-producing cells.

Normal Function

The MIR146A gene provides instructions for making microRNA-146a (miR-146a). Like other microRNAs, this molecule controls gene expression by blocking protein production. It is abundant in immature blood cells and is involved in the growth and division of megakaryocytes, which are the cells responsible for producing platelets involved in blood clotting.

Health Conditions Related to Genetic Changes

5q minus syndrome

The MIR146A gene is involved in 5q minus (5q-) syndrome, a form of myelodysplastic syndrome (MDS). This condition is characterized by the failure of immature blood cells to develop normally, often resulting in anemia and megakaryocyte abnormalities. Individuals with this condition have an increased risk of developing acute myeloid leukemia (AML).

5q- syndrome is caused by a deletion of a region of DNA from the long (q) arm of chromosome 5. This deletion typically spans 1.5 megabases and includes 40 genes, often including MIR146A. The loss of one copy of the MIR146A gene leads to:

  • Reduced levels of miR-146a in cells.
  • Increased levels of proteins that are normally blocked by miR-146a.
  • Abnormal development of megakaryocytes.

Other Names for This Gene

  • hsa-mir-146
  • hsa-mir-146a
  • miR-146a
  • MIRN146
  • MIRN146A
  • miRNA146A

Frequently Asked Questions

Yes. A bone‑marrow cytogenetic analysis (karyotype) or a fluorescence in‑situ hybridization (FISH) panel specifically targeting the 5q31 region can detect the deletion. Many labs also offer a targeted next‑generation sequencing (NGS) panel that includes MIR146A to confirm loss of one allele. Discuss with your hematologist to arrange the appropriate test, which usually requires a peripheral blood or marrow sample.
Reduced miR‑146a levels are associated with a higher AML risk in 5q‑ syndrome. Guidelines suggest regular complete blood counts (CBC) every 1–3 months, bone‑marrow evaluation if blasts rise above 5 % or cytopenias worsen, and annual flow cytometry to detect early clonal evolution. Early referral to a transplant center is advised if high‑risk features appear.
Yes. MIR146A loss disrupts megakaryocyte maturation, often leading to thrombocytopenia. Treatment options include lenalidomide, which has been shown to improve platelet counts in many 5q‑ patients, and supportive care such as platelet transfusions when counts are critically low. Discuss dosing and side‑effects with your hematologist.
Routine screening of asymptomatic relatives is not generally recommended because 5q‑ syndrome usually arises from a somatic deletion rather than an inherited mutation. However, if a family member has unexplained anemia, low platelets, or a personal history of MDS/AML, targeted testing for the 5q deletion can be considered. Genetic counseling can help decide the best approach.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.